Phase III Study of [18F]PSMA-1007 Positron Emission Tomography for the Detection of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorine-18 PSMA 1007 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Diagnostic use; Registrational
Sponsors Advanced Biochemical Compounds (ABX GmbH)

Most Recent Events

30 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Oct 2024.
29 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
14 Nov 2023 This trial has been completed in Netherlands (End Date: 23 Jun 2023), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight